Last update 22 May 2025

GVAX(Dana-Farber Cancer Institute)

Overview

Basic Info

Drug Type
Therapeutic vaccine
Synonyms-
Target-
Action
stimulants
Mechanism
Immunostimulants
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaPhase 2
United States
08 Jan 2013
Anemia, Refractory, With Excess of BlastsPhase 2
United States
08 Jan 2013
Chronic Myelomonocytic LeukemiaPhase 2
United States
08 Jan 2013
Refractory NeuroblastomaPhase 1
United States
29 Jan 2020
Solid tumorPhase 1
United States
29 Jan 2020
Alveolar Soft Part SarcomaPhase 1
United States
01 Jan 2005
Clear Cell SarcomaPhase 1
United States
01 Jan 2005
Clear Cell Sarcoma of KidneyPhase 1
United States
01 Jan 2005
Familial Renal Cell CarcinomaPhase 1
United States
01 Jan 2005
Locally Advanced MelanomaPhase 1
United States
01 Jan 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
123
Allogeneic Hematopoietic Stem Cell Transplant+Fludarabine+Busulfan+Tacrolimus+Methotrexate+GVAX
(GVAX)
wxdeqvgcum = egyzwlajjw drqiaytfzj (daamrssjmb, hbmlabcedh - jcevdmgfal)
-
18 Mar 2022
Allogeneic Hematopoietic Stem Cell Transplant+Fludarabine+Busulfan+Tacrolimus+Methotrexate
(Placebo)
wxdeqvgcum = eracbwqwri drqiaytfzj (daamrssjmb, csgohclasc - muhnzwurki)
Phase 1/2
CD4+CTLA-4+ | CD4+PD-1+ | CD4+IL-5+ ...
28
ufqzmowwil(wxdzolguuf) = Significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4+CTLA-4+, CD4+PD-1+, or differentiated CD8+ T cells, or low pre-treatment frequencies of regulatory T cells. Treatment-induced activation of PB Dendritic Cell subsets was similarly associated with significantly prolonged OS. In contrast, high pre-treatment frequencies of monocytic Myeloid-Derived Suppressor Cells (MDSC) were associated with reduced OS. Th2/Th17 cytokine profiles were induced. Indeed, profound up-regulation of CD4+IL-5+ T cell frequencies was associated with improved OS (p=0.03) and correlated significantly with the breadth of the induced antibody response. IgG antibody responses against 11 (prostate) tumor-associated antigens were determined and increased seroreactivity to prostate-specific membrane antigen (PSMA), pyridoxamine 5'-phosphate oxidase (PNPO) and/or Neuropilin-2 (NRP2) was significantly correlated with improved OS (p=0.002 for combined upregulated seroreactivity to all three). Finally, patients with pre-existing NY-ESO-1 T cell reactivity also demonstrated a significantly prolonged OS (p=0.044) ybvmabghmz (wifjigjrkr )
Positive
12 Mar 2014
Not Applicable
Non-Small Cell Lung Cancer
GMCSF protein production
83
iirrpsygaj(jcnwooykwl) = No significant acute treatment related toxicity was observed axwbjuvlfl (ajybjmqnxd )
Positive
01 May 2007
(Non-vaccinated)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free